Jeff Pelletier Email & Phone Number

Medicinal Chemist with preclinical discovery and early development team leadership experience. Co-nventor of glutamate modulator Troriluzole, a Phase III clinical development candidate for the treatment of ataxia and OCD. Led the IND submission team using collaborator and SBIR grant funding. Managed interdisciplinary, in-house and external CRO contributors to advance three additional chemical entities from Discovery to Development track and early toxicology milestones in big pharma, biotech and academic environments. Co-inventor of MW150 (from NU Feinberg School of Medicine) which has successfully completed Phase I clinical trials. MW150 is a highly selective p38aMAPK inhibitor. Inventor on 28 patents/applications, co-authored 40 presentations and 35 publications. Adaptable with a strong interest in multidiscipline teamwork and rigorous, results driven research.Specialties: -Grant writing-CRO and company collaboration initiation-Medicinal Chemistry-Discovery/Preclinical Development Team building-Discovery/Preclinical Development Team leadership-Discovery to Preclinical Development transitioning-Early development stage chemistry-Parallel, high-throughput synthesis-Multistep organic synthesis-Analytical chemistry-Structure activity relationships-Structure property relationships-Mentoring scientists

Listed skills include Drug Discovery, Medicinal Chemistry, Organic Synthesis, Chemistry, and 8 others.